147 related articles for article (PubMed ID: 33543634)
1. Low Serum Albumin Level Is a Risk Factor for Delayed Methotrexate Elimination in High-Dose Methotrexate Treatment.
Kataoka T; Sakurashita H; Kajikawa K; Saeki Y; Taogoshi T; Matsuo H
Ann Pharmacother; 2021 Oct; 55(10):1195-1202. PubMed ID: 33543634
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
[TBL] [Abstract][Full Text] [Related]
3. Calcium Channel Blockers Possibly Delay the Elimination of Plasma Methotrexate in Patients Receiving High-Dose Methotrexate Therapy.
Inose R; Takahashi K; Nanno S; Hino M; Nagayama K
J Chemother; 2019 Feb; 31(1):30-34. PubMed ID: 30773130
[TBL] [Abstract][Full Text] [Related]
4. A Previously Unknown Drug-Drug Interaction Is Suspected in Delayed Elimination of Plasma Methotrexate in High-Dose Methotrexate Therapy.
Ishizaki J; Nakano C; Kitagawa K; Suga Y; Sai Y
Ann Pharmacother; 2020 Jan; 54(1):29-35. PubMed ID: 31416331
[No Abstract] [Full Text] [Related]
5. Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma.
Misaka KO; Suga Y; Staub Y; Tsubata A; Shimada T; Sai Y; Matsushita R
In Vivo; 2020; 34(6):3459-3465. PubMed ID: 33144454
[TBL] [Abstract][Full Text] [Related]
6. Standardized Supportive Care Documentation Improves Safety of High-Dose Methotrexate Treatment.
Alsdorf WH; Karagiannis P; Langebrake C; Bokemeyer C; Frenzel C
Oncologist; 2021 Feb; 26(2):e327-e332. PubMed ID: 33215763
[TBL] [Abstract][Full Text] [Related]
7. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
8. Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis.
Jian C; Chen S; Wang Z; Zhou Y; Zhang Y; Li Z; Jian J; Wang T; Xiang T; Wang X; Jia Y; Wang H; Gong J
BMC Med Inform Decis Mak; 2023 Aug; 23(1):148. PubMed ID: 37537590
[TBL] [Abstract][Full Text] [Related]
9. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
[TBL] [Abstract][Full Text] [Related]
10. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
Rask C; Albertioni F; Schrøder H; Peterson C
Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
[TBL] [Abstract][Full Text] [Related]
11. Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis.
Wang X; Song Y; Wang J; He J; Liu R; Li X; Huang H; Zhang J
Int J Clin Pharm; 2020 Feb; 42(1):23-30. PubMed ID: 31916121
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia].
Wang H; Chi ZF; Li S; Wang XL; Hao LC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):949-52. PubMed ID: 21867621
[TBL] [Abstract][Full Text] [Related]
13. A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin.
Boerrigter E; Crul M
Ann Pharm Fr; 2017 Sep; 75(5):344-348. PubMed ID: 28705331
[TBL] [Abstract][Full Text] [Related]
14. Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy.
Kagawa Y; Mukohara R; Hori H; Kawasaki H; Komada Y; Kojima M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):34-8. PubMed ID: 15024606
[TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
16. [Clinical application of the simultaneous detection of methotrexate and 7-hydroxymethotrexate in the delayed elimination for pediatric acute lymphoblastic leukemia].
Luo GJ; Wang L; Hu GF; Li CB; Liu HX; Peng MT
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1973-1978. PubMed ID: 32629599
[No Abstract] [Full Text] [Related]
17. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
[TBL] [Abstract][Full Text] [Related]
18. The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients.
Traivaree C; Likasitthananon N; Monsereenusorn C; Rujkijyanont P
Cancer Manag Res; 2018; 10():4471-4478. PubMed ID: 30349379
[TBL] [Abstract][Full Text] [Related]
19. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
20. Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury.
Sakran R; Milo G; Jabareen A; Artul T; Haim N; Litvak M; Ringelstein-Harlev S; Horowitz N; Efrati E; Assady S; Kurnik D
J Oncol Pharm Pract; 2022 Mar; 28(2):508-515. PubMed ID: 34668443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
